Vonoprazan hydrochloride

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1957202-44-6

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

TAK-438 hydrochloride

产品介绍

Vonoprazan hydrochloride 是一种质子泵抑制剂 (PPI)，是高效的，具有口服活性的钾竞争性酸阻断剂 (potassium-competitive acid blocker, P-CAB)，具有抗分泌活性。在 pH 为 6.5 时，Vonoprazan hydrochloride抑制猪胃微粒体中的 H⁺,K⁺-ATPase 酶活性，IC₅₀值为 19 nM。Vonoprazan hydrochloride 被开发用于研究胃酸相关疾病，如胃食管反流病和消化性溃疡。Vonoprazan hydrochloride 可用于根除幽门螺杆菌。

生物活性

Vonoprazan hydrochloride, aproton pump inhibitor(PPI), is a potent and orally activepotassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H⁺,K⁺-ATPase activity in porcine gastric microsomes with anIC₅₀of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication ofHelicobacter pylori^[1]^[2]^[3].

IC₅₀& Target

IC₅₀: 19 nM (porcine gastric H⁺,K⁺-ATPase, at pH 6.5)^[2]

体外研究
(In Vitro)

Vonoprazan (0.1 nM-10 μM; 30 minutes) exhibits porcine gastric H⁺, K⁺-ATPase activity in a concentration-dependent manner^[2].
Vonoprazan does not inhibit Na⁺,K⁺-ATPase activity, even at concentrations 500 times higher than their IC₅₀values against gastric H⁺,K⁺-ATPase activity^[2].

体内研究
(In Vivo)

Vonoprazan (1-4 mg/kg; p.o.) completely inhibits basal and 2-deoxy-D-glucose (200 mg/kg; s.c.)-stimulated gastric acid secretion at the 4 mg/kg dose in rats^[2].

Animal Model:	Male 7- or 8-week-old Sprague-Dawley rat^[2]
Dosage:	0.5 mg/kg, 1 mg/kg, 2 mg/kg, 4 mg/kg
Administration:	Oral administration
Result:	Inhibited basal gastric acid secretion in a dose-dependent manner.

Clinical Trial

分子量

381.85

Formula

C₁₇H₁₇ClFN₃O₂S

CAS 号

1957202-44-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.